Previous close | 3.2500 |
Open | 2.3800 |
Bid | 2.1100 |
Ask | 2.2300 |
Strike | 140.00 |
Expiry date | 2024-06-21 |
Day's range | 1.1500 - 2.8000 |
Contract range | N/A |
Volume | |
Open interest | 2.7k |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.